This rate is comparable to that observed in ET and highlights the significant risk of thrombosis in PMF patients, particularly those with the JAK2 V617F mutation and leukocytosis [7]. Elliot et al. reported an incidence of thrombotic events of 13.2% at or prior to diagnosis, and 10.7% over a median follow-up of 31 months in a series of 208 patients [8]. This evidence concerns the gene JAK2 and essential thrombocythemia.